|
WO2021078227A1
|
|
Fused heteroaryl derivative, preparation method therefor, and application thereof in medicine
|
|
WO2021063340A1
|
|
Use of ezh2 inhibitor in combination with immune checkpoint inhibitor and tyrosine kinase inhibitor in preparation of medication for treating tumor
|
|
WO2021063332A1
|
|
Use of ezh2 inhibitor combined with cdk4/6 inhibitor in preparation of drug for treating tumor
|
|
WO2021058027A1
|
|
Pyrrolo heteroaryl derivative or conjugate thereof, preparation method therefor and application thereof
|
|
WO2021063331A1
|
|
USE OF COMBINATION OF EZH2 INHIBITOR AND TGF-β RECEPTOR-CONTAINING FUSION PROTEIN IN PREPARATION OF DRUGS FOR TREATING TUMORS
|
|
WO2021057764A1
|
|
Use of pd-1 antibody in combination with taxoid compound in preparation of drugs for treating triple-negative breast cancer
|
|
WO2021047573A1
|
|
Use of mek inhibitor in combination with cdk4/6 inhibitor in preparation of drugs for treating tumors
|
|
WO2021037185A1
|
|
Tyrosine kinase inhibitor having low impurity content
|
|
WO2021037199A1
|
|
Transdermal amide local anesthetic-containing pharmaceutical composition and preparation method therefor
|
|
WO2021032074A1
|
|
Benzamide fused aromatic ring derivative, preparation method therefor and application thereof in medicine
|
|
WO2021023204A1
|
|
Use of cdk4/6 inhibitor in combination with multi-target tyrosine kinase inhibitor in preparing medicament for treating tumor
|
|
WO2021023178A1
|
|
Use of pyrrolo-fused six-membered heterocyclic compound in preparation of medicament for treating fgfr2 gene mutation tumor
|
|
WO2021018165A1
|
|
Pyridine benzamide derivative, preparation method for same, and medicinal applications thereof
|
|
WO2021018191A1
|
|
Method for treating autoimmune disease by il-17 antagonist
|
|
WO2021018112A1
|
|
Preparation method of 1,6-dihydropyridine-3-carboxamide derivative
|
|
WO2021013142A1
|
|
Anti-4-1bb antibody, antigen-binding fragment thereof, and bispecific antibody
|
|
WO2021000885A1
|
|
Quinazoline derivatives, preparation process and medical use thereof
|
|
WO2020259667A1
|
|
Use of combination of tlr agonist and anti-ox40 antibody or antigen binding fragment thereof in preparation of medicament for treating tumors
|
|
WO2020259670A1
|
|
Sustained-release lipid composition and preparation method therefor
|
|
WO2020259550A1
|
|
Anti-cea antibody and application thereof
|
